Vivaldi Capital Management LLC reduced its position in shares of CME Group Inc (NASDAQ:CME) by 34.5% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,320 shares of the financial services provider’s stock after selling 3,848 shares during the quarter. Vivaldi Capital Management LLC’s holdings in CME Group were worth $1,421,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Girard Partners LTD. grew its stake in shares of CME Group by 3.1% in the second quarter. Girard Partners LTD. now owns 4,363 shares of the financial services provider’s stock worth $847,000 after acquiring an additional 130 shares during the period. Prime Capital Investment Advisors LLC grew its position in CME Group by 59.5% during the second quarter. Prime Capital Investment Advisors LLC now owns 319 shares of the financial services provider’s stock valued at $62,000 after buying an additional 119 shares during the period. Fox Run Management L.L.C. bought a new stake in CME Group during the second quarter valued at approximately $571,000. Aperio Group LLC grew its position in CME Group by 3.7% during the second quarter. Aperio Group LLC now owns 210,967 shares of the financial services provider’s stock valued at $40,951,000 after buying an additional 7,573 shares during the period. Finally, Jackson Hole Capital Partners LLC grew its position in CME Group by 4.1% during the first quarter. Jackson Hole Capital Partners LLC now owns 1,986 shares of the financial services provider’s stock valued at $327,000 after buying an additional 79 shares during the period. Institutional investors and hedge funds own 84.85% of the company’s stock.
In other news, insider Sean Tully sold 7,200 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $223.13, for a total value of $1,606,536.00. Following the transaction, the insider now owns 19,923 shares of the company’s stock, valued at $4,445,418.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO John W. Pietrowicz sold 2,500 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $201.30, for a total transaction of $503,250.00. Following the completion of the transaction, the chief financial officer now directly owns 32,854 shares in the company, valued at approximately $6,613,510.20. The disclosure for this sale can be found here. Insiders sold 59,626 shares of company stock worth $12,255,934 in the last three months. Insiders own 1.20% of the company’s stock.
CME Group (NASDAQ:CME) last issued its quarterly earnings results on Wednesday, July 31st. The financial services provider reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.01. CME Group had a net margin of 39.36% and a return on equity of 9.14%. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the previous year, the firm earned $1.74 earnings per share. The company’s revenue for the quarter was up 20.1% on a year-over-year basis. Equities analysts forecast that CME Group Inc will post 6.73 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Stockholders of record on Tuesday, September 10th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.42%. The ex-dividend date is Monday, September 9th. CME Group’s dividend payout ratio (DPR) is presently 43.99%.
Several analysts recently issued reports on the stock. Oppenheimer assumed coverage on shares of CME Group in a research report on Monday. They set an “outperform” rating and a $234.00 target price for the company. Berenberg Bank lowered shares of CME Group from a “buy” rating to a “hold” rating and cut their target price for the company from $236.00 to $227.00 in a research report on Thursday. Barclays boosted their target price on shares of CME Group from $191.00 to $197.00 and gave the company an “overweight” rating in a research report on Thursday, May 23rd. Zacks Investment Research lowered shares of CME Group from a “hold” rating to a “sell” rating and set a $158.00 target price for the company. in a research report on Monday, May 27th. Finally, Deutsche Bank boosted their target price on shares of CME Group from $224.00 to $240.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. CME Group presently has a consensus rating of “Hold” and a consensus price target of $200.00.
CME Group Profile
CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.
Featured Article: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.